Randomised clinical trial: Pregabalin attenuates the development of acid-induced oesophageal hypersensitivity in healthy volunteers - A placebo-controlled study

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 3, 2012, Pages 319-326

  Chua, Y C ^a   Ng, K S ^a   Sharma, A ^b   Jafari, J ^a   Surguy, S ^a   Yazaki, E ^a   Knowles, C H ^a   Aziz, Q ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACID; PLACEBO; PREGABALIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG ACTIVITY; ELECTRODE; ELECTROSTIMULATION; ESOPHAGUS DISEASE; ESOPHAGUS HYPERSENSITIVITY; ESOPHAGUS MANOMETRY; ESOPHAGUS PAIN; EUPHORIA; FEMALE; HUMAN; HYPERSENSITIVITY; MALE; MORNING DOSAGE; PAIN THRESHOLD; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIZATION; SIDE EFFECT; VISUAL ANALOG SCALE; VOLUNTEER;

ADULT; ANALGESICS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ESOPHAGEAL DISEASES; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; HYDROCHLORIC ACID; HYDROGEN-ION CONCENTRATION; HYPERSENSITIVITY; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84855341203     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04955.x     Document Type: Article

References (46)

1. Isolauri J, Laippala P,. Prevalence of symptoms suggestive of gastro-oesophageal reflux disease in an adult population. Ann Med 1995; 27: 67-70.
2. Fass R,. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol 2007; 41: 131-7. (Pubitemid 46148652)
3. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-80. (Pubitemid 29333764)
4. Kahrilas PJ, Quigley EM,. Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterology 1996; 110: 1982-96.
5. Knowles CH, Aziz Q,. Visceral hypersensitivity in non-erosive reflux disease. Gut 2008; 57: 674-83. (Pubitemid 351579984)
6. Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R,. Non-erosive reflux disease (NERD)-acid reflux and symptom patterns. Aliment Pharmacol Ther 2003; 17: 537-45. (Pubitemid 36384812)
7. Nagahara A, Miwa H, Minoo T, et al. Increased esophageal sensitivity to acid and saline in patients with nonerosive gastro-esophageal reflux disease. J Clin Gastroenterol 2006; 40: 891-5. (Pubitemid 44690761)
8. Farre R, De Vos R, Geboes K, et al. Critical role of stress in increased oesophageal mucosa permeability and dilated intercellular spaces. Gut 2007; 56: 1191-7. (Pubitemid 47300417)
9. Carlsson R, Fandriks L, Jonsson C, Lundell L, Orlando RC,. Is the esophageal squamous epithelial barrier function impaired in patients with gastroesophageal reflux disease? Scand J Gastroenterol 1999; 34: 454-8. (Pubitemid 29307812)
10. Tobey NA, Carson JL, Alkiek RA, Orlando RC,. Dilated intercellular spaces: a morphological feature of acid reflux-damaged human esophageal epithelium. Gastroenterology 1996; 111: 1200-5. (Pubitemid 26362244)
11. Sarkar S, Thompson DG, Woolf CJ, Hobson AR, Millane T, Aziz Q,. Patients with chest pain and occult gastroesophageal reflux demonstrate visceral pain hypersensitivity which may be partially responsive to acid suppression. Am J Gastroenterol 2004; 99: 1998-2006. (Pubitemid 39421246)
12. Bredenoord AJ, Smout AJ,. Refractory gastrooesophageal reflux disease. Eur J Gastroenterol Hepatol 2008; 20: 217-23. (Pubitemid 351317360)
13. Broeders JA, Draaisma WA, Bredenoord AJ, et al. Oesophageal acid hypersensitivity is not a contraindication to Nissen fundoplication. Br J Surg 2009; 96: 1023-30.
14. Sarkar S, Aziz Q, Woolf CJ, Hobson AR, Thompson DG,. Contribution of central sensitisation to the development of non-cardiac chest pain. Lancet 2000; 356: 1154-9.
15. Sarkar S, Hobson AR, Hughes A, et al. The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans. Gastroenterology 2003; 124: 18-25. (Pubitemid 36055334)
16. Willert RP, Delaney C, Hobson AR, Thompson DG, Woolf CJ, Aziz Q,. Constitutive cyclo-oxygenase-2 does not contribute to the development of human visceral pain hypersensitivity. Eur J Pain 2006; 10: 487-94. (Pubitemid 43947638)
17. Willert RP, Hobson AR, Delaney C, Hicks KJ, Dewit OE, Aziz Q,. Neurokinin-1 receptor antagonism in a human model of visceral hypersensitivity. Aliment Pharmacol Ther 2007; 25: 309-16. (Pubitemid 46115400)
18. Willert RP, Woolf CJ, Hobson AR, Delaney C, Thompson DG, Aziz Q,. The development and maintenance of human visceral pain hypersensitivity is dependent on the N-methyl-D-aspartate receptor. Gastroenterology 2004; 126: 683-92. (Pubitemid 38298316)
19. Dooley DJ, Donovan CM, Meder WP, Whetzel SZ,. Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices. Synapse 2002; 45: 171-90. (Pubitemid 34827361)
20. Ben-Menachem E,. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004; 45 (Suppl. 6): 13-8. (Pubitemid 39350325)
21. Errante LD, Petroff OA,. Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure 2003; 12: 300-6. (Pubitemid 36806076)
22. Luszczki JJ,. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep 2009; 61: 197-216.
23. Bech P,. Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiatry 2007; 40: 163-8. (Pubitemid 47434876)
24. Siddall PJ, Cousins MJ, Otte A, Griesing T, Chambers R, Murphy TK,. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology 2006; 67: 1792-800. (Pubitemid 44900755)
25. Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE,. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005; 6: 253-60. (Pubitemid 40488803)
26. Lesser H, Sharma U, LaMoreaux L, Poole RM,. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004; 63: 2104-10. (Pubitemid 39636259)
27. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 1264-73. (Pubitemid 40530135)
28. Serra E,. Duloxetine and pregabalin: safe and effective for the long-term treatment of fibromyalgia? Nat Clin Pract Neurol 2008; 4: 594-5.
29. Lyseng-Williamson KA, Siddiqui MA,. Pregabalin: a review of its use in fibromyalgia. Drugs 2008; 68: 2205-23.
30. Iturrino J, Camilleri M, Busciglio I, Burton D, Zinsmeister AR,. Effect of the alpha2delta ligand, pregabalin, on colonic sensory and motor functions in healthy adults. Am J Physiol Gastrointest Liver Physiol 2011; 301: G377-84.
31. Houghton LA, Fell C, Whorwell PJ, Jones I, Sudworth DP, Gale JD,. Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 2007; 56: 1218-25. (Pubitemid 47300421)
32. Schulz KF, Altman DG, Moher D,. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340: c332.
33. Sharma A, Van Oudenhove L, Paine P, Gregory L, Aziz Q,. Anxiety increases acid-induced esophageal hyperalgesia. Psychosom Med 2010; 72: 802-9.
34. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003; 60: 1274-83. (Pubitemid 36460982)
35. Frampton JE, Scott LJ,. Pregabalin: in the treatment of painful diabetic peripheral neuropathy. Drugs 2004; 64: 2813-20. discussion 2821. (Pubitemid 40007486)
36. Chua YC HA, Sharma A, Willert RP, Aziz Q,. Quantifying the magnitude and variability of esophageal sensitisation which develops following human experimental esophageal acidification. Gastroenterology 2008; 134 (Suppl. 1): A-719-20.
37. Bockbrader HN, Radulovic LL, Posvar EL, et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol 2010; 50: 941-50.
38. Willert RP HA, Woolf CJ, Thompson DG, Aziz Q,. Ketamine, an NMDA receptor antagonist prevents the induction of central sensitisation in a human model of visceral pain hypersensitivity. Gut 2003; 52: A15.
39. Frame B, Miller R, Hutmacher MM,. Joint modeling of dizziness, drowsiness, and dropout associated with pregabalin and placebo treatment of generalized anxiety disorder. J Pharmacokinet Pharmacodyn 2009; 36: 565-84.
40. Hill DR, Suman-Chauhan N, Woodruff GN,. Localization of [3H]gabapentin to a novel site in rat brain: autoradiographic studies. Eur J Pharmacol 1993; 244: 303-9. (Pubitemid 23051253)
41. Wallin J, Cui JG, Yakhnitsa V, Schechtmann G, Meyerson BA, Linderoth B,. Gabapentin and pregabalin suppress tactile allodynia and potentiate spinal cord stimulation in a model of neuropathy. Eur J Pain 2002; 6: 261-72. (Pubitemid 35177563)
42. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M,. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005; 115: 254-63. (Pubitemid 40725282)
43. Diop L, Raymond F, Fargeau H, Petoux F, Chovet M, Doherty AM,. Pregabalin (CI-1008) inhibits the trinitrobenzene sulfonic acid-induced chronic colonic allodynia in the rat. J Pharmacol Exp Ther 2002; 302: 1013-22. (Pubitemid 34920221)
44. Eutamene H, Coelho AM, Theodorou V, et al. Antinociceptive effect of pregabalin in septic shock-induced rectal hypersensitivity in rats. J Pharmacol Exp Ther 2000; 295: 162-7.
45. Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R,. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2: 656-64. (Pubitemid 39013424)
46. Tutuian R, Vela MF, Hill EG, Mainie I, Agrawal A, Castell DO,. Characteristics of symptomatic reflux episodes on acid suppressive therapy. Am J Gastroenterol 2008; 103: 1090-6. (Pubitemid 351677992)